Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE).
Shi Y, Chen J, Yang R, Wu H, Wang Z, Yang W, Cui J, Zhang Y, Liu C, Cheng Y, Liu Y, Shan J, Wang D, Yang L, Hu C, Zhao J, Cao R, Tan B, Xu K, Si M, Li H, Mao R, Li L, Kang X, Wang L.
Shi Y, et al. Among authors: li h, li l.
J Thorac Oncol. 2024 Jan 25:S1556-0864(24)00033-9. doi: 10.1016/j.jtho.2024.01.013. Online ahead of print.
J Thorac Oncol. 2024.
PMID: 38280448
Free article.